Migraine Research in Phoenix: Understanding the PHASES Ubrelvy Observational Study

Migraine can affect work, family time, sleep, and plans that matter. For adults in Arizona who use or have been prescribed ubrogepant, learning about research may bring up practical questions: Is this a treatment study? Would participation change my care? What information do researchers collect? Arizona Neuroscience Research currently lists PHASES, study P25-590, among its enrolling studies. PHASES is described as an observational study of adults with migraine who use ubrogepant, also known by the brand name Ubrelvy.

This overview explains what the public study listing says, how an observational migraine study differs from a treatment trial, and what to ask before considering screening in Phoenix. It is educational and does not replace advice from the clinician who manages your migraine care.

What is the PHASES P25-590 study?

Arizona Neuroscience Research describes PHASES (P25-590) as an observational study evaluating changes in migraine attack severity in adults using oral ubrogepant. The public listing identifies AbbVie as the sponsor and directs visitors to current study information and the research site for details. An observational study records specific information over time; it does not use the same design as a study that assigns a new investigational treatment to participants.

The term observational does not mean that participation is casual or without procedures. A study may still include screening, informed consent, questionnaires, records, visits, or contacts. The research team will explain the exact protocol, including what information is collected, how long participation may last, and what is expected of someone who joins. Public listings are useful starting points, but they do not replace the consent discussion or local screening process.

Arizona Neuroscience Research currently lists PHASES as enrolling. Local availability can change, and eligibility is determined by the study team using the current protocol. A person can ask for information without committing to participate.

Understanding migraine beyond a bad headache

Migraine is a neurologic condition. A migraine attack may include headache pain, nausea, vomiting, sensitivity to light or sound, dizziness, sensory changes, or other symptoms. Some people experience an aura, while others do not. Frequency, severity, triggers, and symptoms can differ from one person to another, which is why a personal pattern should be discussed with a clinician rather than compared too closely with someone else’s experience.

Keeping a simple record can make those conversations clearer. Some people note when an attack starts, symptoms, possible triggers, how the attack affected activities, and what treatment was used. A research study may ask for certain information in a specified way. That study information serves the research question and should not be treated as a substitute for a personal treatment plan.

A change in headache pattern deserves attention. Seek emergency help for a sudden, severe headache unlike usual symptoms, a headache with new weakness, trouble speaking, fainting, a seizure, confusion, or a new neurologic symptom. For recurring or worsening migraine symptoms that are not an emergency, contact your treating clinician promptly.

What observational research can and cannot show

Observational research looks at care that is already taking place. PHASES is described as studying participants who use oral ubrogepant and assessing changes in migraine attack severity. It does not promise a benefit, a certain result, or a particular treatment decision for an individual. Researchers can examine patterns across participants, but those patterns do not predict what will happen for any one person.

This differs from a randomized treatment trial. In a randomized trial, a protocol may assign participants to study groups. In an observational study, researchers gather specified information about treatment use and outcomes in routine care. Both kinds of research can be useful, but they answer different questions. The site staff can explain the PHASES design in plain language, including whether a person needs to be using ubrogepant before screening.

What PHASES does not promise

• It does not promise that someone will qualify or be enrolled.
• It does not promise relief from migraine attacks or a change in their severity.
• It does not replace regular migraine care or emergency care.
• It does not mean a person should start, stop, or change medication based on a study listing.
• It does not guarantee that the study remains available at the Phoenix site.

Ubrogepant and research participation

Ubrogepant is the generic name for Ubrelvy. The PHASES listing concerns adults with migraine who are using oral ubrogepant. A study listing is not a recommendation to use any medicine. Medication choices depend on diagnosis, medical history, other medicines, potential interactions, pregnancy considerations, and an individual conversation with the clinician managing care.

If you are interested in PHASES, a useful question is how the study relates to your current plan. Ask whether the study observes treatment already prescribed in routine care, what the protocol requires, and who should answer medication questions. The research team can explain the study. Your treating clinician can advise you about your own medical care. Those roles may overlap in useful ways, but they are not identical.

What screening and informed consent may involve

Before enrollment, the research team reviews the study and checks whether a person may fit the protocol. This is screening. It may include questions about age, migraine history, current and past treatments, other health conditions, and study-specific criteria. The site may ask for medical records or other information relevant to the protocol. Screening does not guarantee that someone will be enrolled.

If screening suggests the study may fit, the team should provide informed-consent materials. Informed consent is a conversation, not merely a form. It should cover the study’s purpose, procedures, possible risks or inconveniences, privacy, alternatives, voluntary participation, and whom to contact with questions. Read the material at your own pace. It is appropriate to ask for a plain-language explanation or to discuss it with people you trust.

You can decide not to participate, even after learning more. No one should feel pressured to join a research study. A careful choice is based on current information, an understanding of the commitment involved, and your own circumstances.

Questions to ask Arizona Neuroscience Research

Consider bringing a short list of questions to a call or visit:

• Is PHASES (P25-590) currently enrolling in Phoenix?
• Who may be considered for screening under the current protocol?
• Does the study require current use of ubrogepant, and what documentation is needed?
• What visits, surveys, diaries, or follow-up contacts are involved?
• How long does participation last?
• What information does the study collect about migraine attacks and treatment use?
• How does participation relate to my usual migraine care?
• Who should I contact about a new symptom or a medication concern?

Questions like these do not determine eligibility. They help people understand whether an initial screening conversation makes sense.

Keeping migraine care and research connected

Research participation should fit within, not replace, your care plan. Continue follow-up with the clinician who manages your migraines, and do not delay needed care while waiting to hear about a study. Bring an updated medication list to any screening conversation. If you use a headache diary, ask whether the study has its own format or tools and whether your usual record should continue separately.

Be honest about how migraine affects everyday life. Research staff may need accurate information about symptom patterns, treatment use, and health history. Clear answers help the team determine whether the protocol is a match and help participants understand what the study can realistically involve.

Frequently asked questions about PHASES

Is PHASES a clinical trial?

PHASES is clinical research, described by Arizona Neuroscience Research as an observational study. It evaluates changes in migraine attack severity in adults using oral ubrogepant. The team can explain its current design and procedures.

Does PHASES provide Ubrelvy?

The public listing describes PHASES as an observational study of people using ubrogepant. Do not assume what a study provides. Ask the site staff about the protocol and discuss medication decisions with your treating clinician.

Can anyone with migraine join?

No. The study team uses the current protocol to determine eligibility. Having migraine or being interested in research is not enough on its own to establish that someone qualifies.

Is Arizona Neuroscience Research enrolling?

Arizona Neuroscience Research currently lists PHASES as enrolling. Because local status can change, confirm current availability directly with the research team.

Where can I learn more?

Visit Arizona Neuroscience Research’s Current Studies page, review the sponsor’s PHASES study information, and submit an inquiry through Volunteer Today.

Next steps for Phoenix adults interested in migraine research

Start with current information. Review the PHASES listing, then contact Arizona Neuroscience Research to ask whether the study is still open locally and whether screening may be appropriate. The research team can explain the present protocol, practical expectations, and next steps. Arizona Neuroscience Research lists Phoenix locations near Bell Road and in the Biltmore area; use the current website for contact details.

Research is voluntary. You can ask questions, take time to consider the information, and decide that participation is not right for you. The goal of a good screening conversation is clear understanding, not pressure.

This article is for education and does not provide medical advice, diagnosis, or treatment. Study eligibility, local availability, procedures, risks, and potential benefits must be reviewed with the research team and a participant’s treating clinician.

Making an informed choice about an observational migraine study

Before you contact a research site, think about the practical details that matter to you. You may want to ask how appointments fit with work or caregiving, whether visits are in person or remote, how symptom information is recorded, and what happens if your routine care changes. It is also helpful to bring a current medicine list, including over-the-counter products and supplements, because the protocol may ask for a complete picture of treatment use.

Take time to understand the difference between information collected for research and decisions made for your own care. A study may ask about headache severity, timing, symptoms, and how an attack affected activities. Your personal clinician may use some of the same information for care, but the purposes are different. Ask the research team how it handles new safety concerns, who receives study information, and whether you should continue contacting your usual clinician for routine questions.

A thoughtful decision can include family members or another trusted person if you wish. You may ask to take consent materials home, write down questions, and return for answers. If participating is not right for you, that choice is valid. If you move forward, the study team can explain the current process step by step.

For many people, the practical questions are as important as the medical ones. Ask how to reach the study team, what information you may receive after enrollment, and whether transportation or scheduling considerations should be discussed before screening. Understanding the process helps you decide with confidence.

Ask questions, take time, and choose freely.

Your questions deserve clear answers before enrollment.